Showing 759 news articles about Hepatitis C treatment

Filters Content type: Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment

Clash between state, drugmaker heats up as Legislature takes up Hepatitis C cost

Editor's pick
The Oregonian
16 September 2014
Hepatitis C treatment

Gilead signs pact with 7 firms for cheap copies of hepatitis C drug

Editor's pick
Reuters
15 September 2014
Hepatitis C treatment

Simeprevir in hepatitis C: added benefit for certain patients

Editor's pick
German Institute for Quality and Efficiency in Health Care
10 September 2014
Access to healthcare

Gilead close to sending $84,000 drug to poor countries

Editor's pick
Bloomberg
9 September 2014
Hepatitis C treatment

Doctors Battle Insurers for Access to Pricey Hepatitis C Drugs

Editor's pick
Healthline
9 September 2014
Hepatitis C treatment

MSF urges BMS to make daclatasvir accessible in low-and middle-income countries

Editor's pick
Pharmabiz
1 September 2014
New & experimental hepatitis C treatment

European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

Editor's pick
Bristol-Myers Squibb
27 August 2014
Hepatitis C treatment

The Risky Business of Limiting Medicaid Access to Sovaldi

Editor's pick
Governing
21 August 2014
Hepatitis C treatment

Nearly Half of Surveyed US Specialists Expect to Prescribe Gilead's Sofosbuvir / Ledipasvir Regimen Near-Term for Hepatitis C Infections

Editor's pick
Decision Resources Group press release
21 August 2014
Hepatitis C treatment

Britain Has No Problem Paying for Expensive Hepatitis C Drugs

Editor's pick
Businessweek
19 August 2014
New & experimental hepatitis C treatment

Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

Editor's pick
Achillion press release
18 August 2014
Hepatitis C treatment

NICE consults on further draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C

Editor's pick
NICE
15 August 2014
Hepatitis C treatment

UK cost body backs pricey Gilead hepatitis pill for some patients

Editor's pick
Reuters
15 August 2014
Hepatitis C treatment

OTP patients, ideal for new hepatitis C medication, put on bottom of list by payers

Editor's pick
Alcohol & Drug Abuse Weekly
14 August 2014
Hepatitis C treatment

Vertex to stop selling hepatitis C drug Incivek, once a blockbuster, in October

Editor's pick
Boston Business Journal (blog)
13 August 2014
Hepatitis C treatment

Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices

Editor's pick
Fierce Pharma
11 August 2014
Prisoners

Why the Hepatitis Cure Sovaldi Is a Budgetary Disaster for Prisons

Editor's pick
New York Times
7 August 2014
Hepatitis C treatment

What Will the new Hepatitis C Medicines do to Medicare Part D?

Editor's pick
Wall Street Journal
5 August 2014
Hepatitis C treatment

Study predicts hepatitis C will become a rare disease in 22 years

Editor's pick
Eurekalert Medicine & Health
5 August 2014
Hepatitis C treatment

Call to EU Ministers of health and CEOs of Abbvie, BMS, Gilead, Janssen and Merck/MSD regarding universal access to curative hepatitis C treatment in the EU and beyond

Editor's pick
EATG
30 July 2014
Hepatitis C symptoms & diagnosis

Hepatitis C annual report: progress made, but much more to do

Editor's pick
Public Health England
28 July 2014
Hepatitis C treatment

In patients co-infected with HIV, combination antiretroviral therapy helps treat HCV

Editor's pick
HIV / AIDS News From Medical News Today
25 July 2014
Pharmaceutical industry

Gilead's Sovaldi soars with sales of $3.48 billion

Editor's pick
Pharma Times
25 July 2014
Hepatitis C treatment

Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug

Editor's pick
Treatment Action Group
25 July 2014